Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Caceres – page 6

151 clinical trials in Caceres, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Caceres at a glance
151
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

151 trials in Caceres

Open in trial search

Seasonal allergy

Not yet recruiting

Study to Find the Best Dose of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis, with or without Asthma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
  • Sponsor:Probelte Pharma S.L.

Acute leukaemia+2

Not yet recruiting

Study Comparing Fosfomycin and Ciprofloxacin for Preventing Fever in Patients with Acute Leukemia After Chemotherapy or Stem Cell Transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Fundacion Para La Investigacion Y La Innovacion Biosanitaria Del Principado De Asturias

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety and Effects of AB8939 and Azacitidine for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ab Science

Breast cancer female

Not yet recruiting

Study of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Michelangelo

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Chronic obstructive pulmonary disease

Not recruiting

Study of Verekitug to improve symptoms in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Polatuzumab Vedotin, Rituximab, and CHP in Patients with Untreated Diffuse Large B-Cell Lymphoma

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Polatuzumab Vedotin
  • Sponsor:F. Hoffmann-La Roche AG

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effects of Astegolimab and Drug Combination for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Genentech Inc.

Bladder cancer

Not recruiting

Study of Sasanlimab with BCG or Alone for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Not Responding to BCG

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sasanlimab
  • Sponsor:Pfizer Inc.

Acute myeloid leukaemia+1

Not recruiting

Study of RVU120 for Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
  • Sponsor:Ryvu Therapeutics S.A.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Caceres

What the registry says about research in the country

01 Hematologic Malignancies

Clinical trials focusing on acute myeloid leukemia and related blood disorders, evaluating novel therapeutic combinations and treatment approaches.

  • Leukemia treatments
  • Drug combinations
  • Therapy resistance

Studies include investigations of eganelisib, RVU120, and other promising compounds for refractory conditions.

02 Cardiovascular Research

Innovative trials examining treatments for coronary artery disease and related cardiovascular conditions, including specialized therapies for arterial dissection.

  • Antiplatelet therapy
  • Stent technologies
  • Cardiovascular prevention

Research includes evaluation of novel medications and therapeutic approaches for various cardiac conditions.

03 Oncology Studies

Comprehensive research in breast cancer and melanoma, investigating targeted therapies and combination treatments for various cancer types.

  • Targeted therapies
  • Immunotherapy
  • Treatment resistance

Multiple trials exploring innovative treatment approaches for both early-stage and advanced cancers.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.